ArticleBMJ oncology2025

UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results.

D Gareth Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.